GuangYuYuan Chinese Herbal Medicine Co., Ltd. (SHA:600771)
China · Delayed Price · Currency is CNY 17.86
+0.12 (0.68%)
At close: Feb 3, 2026
SHA:600771 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,387 | 1,220 | 1,283 | 1,116 | 849.3 | 1,107 |
Other Revenue | 1.21 | 1.21 | 1.34 | 14.53 | 4.93 | 2.09 |
| 1,389 | 1,221 | 1,284 | 1,131 | 854.22 | 1,109 | |
Revenue Growth (YoY) | 15.04% | -4.88% | 13.56% | 32.37% | -23.00% | -8.85% |
Cost of Revenue | 438.81 | 329.93 | 350.72 | 404.77 | 333.11 | 325.96 |
Gross Profit | 949.81 | 891.49 | 933.3 | 725.95 | 521.11 | 783.47 |
Selling, General & Admin | 689.78 | 665.54 | 736.08 | 881.9 | 867.33 | 660.84 |
Research & Development | 41.72 | 38.59 | 31.38 | 28.96 | 25.19 | 43.44 |
Other Operating Expenses | 38.17 | 26.57 | 27.9 | 19.57 | 17.46 | 15.58 |
Operating Expenses | 836.25 | 800.06 | 820.11 | 952.63 | 883.95 | 770.26 |
Operating Income | 113.56 | 91.43 | 113.18 | -226.68 | -362.84 | 13.21 |
Interest Expense | -1.55 | -6.43 | -16.94 | -20.95 | -19.09 | -12.94 |
Interest & Investment Income | 1.61 | 1.77 | 2.97 | 0.97 | 4.94 | 1.76 |
Earnings From Equity Investments | - | - | - | -0.92 | - | - |
Other Non Operating Income (Expenses) | 6.67 | -0.76 | -0.41 | -6.89 | -10.5 | -27.84 |
EBT Excluding Unusual Items | 120.29 | 86.01 | 98.81 | -254.48 | -387.48 | -25.8 |
Gain (Loss) on Sale of Investments | -6.87 | -7.73 | - | - | -4.22 | -2.27 |
Gain (Loss) on Sale of Assets | 0 | -0.02 | 0.2 | -0.02 | 0.37 | 0.88 |
Asset Writedown | -4.55 | -4.71 | -0.02 | -19.89 | - | - |
Other Unusual Items | 0.42 | 7.29 | 1.39 | 9.25 | 38.7 | 44.7 |
Pretax Income | 109.28 | 80.85 | 100.37 | -265.13 | -352.63 | 17.51 |
Income Tax Expense | 23.86 | -2.75 | 7.52 | -2.13 | -20.2 | -12.07 |
Earnings From Continuing Operations | 85.43 | 83.6 | 92.85 | -263.01 | -332.43 | 29.58 |
Minority Interest in Earnings | -3.06 | -9.15 | -2.77 | 12.98 | 16.19 | 2.43 |
Net Income | 82.37 | 74.45 | 90.08 | -250.02 | -316.24 | 32 |
Net Income to Common | 82.37 | 74.45 | 90.08 | -250.02 | -316.24 | 32 |
Net Income Growth | 18.54% | -17.35% | - | - | - | -75.39% |
Shares Outstanding (Basic) | 486 | 496 | 500 | 490 | 494 | 457 |
Shares Outstanding (Diluted) | 486 | 496 | 500 | 490 | 494 | 457 |
Shares Change (YoY) | -6.41% | -0.82% | 2.08% | -0.79% | 8.08% | -8.61% |
EPS (Basic) | 0.17 | 0.15 | 0.18 | -0.51 | -0.64 | 0.07 |
EPS (Diluted) | 0.17 | 0.15 | 0.18 | -0.51 | -0.64 | 0.07 |
EPS Growth | 26.65% | -16.67% | - | - | - | -73.08% |
Free Cash Flow | 168.94 | 103.61 | 212.99 | 244.76 | 63.17 | -125.17 |
Free Cash Flow Per Share | 0.35 | 0.21 | 0.43 | 0.50 | 0.13 | -0.27 |
Gross Margin | 68.40% | 72.99% | 72.69% | 64.20% | 61.00% | 70.62% |
Operating Margin | 8.18% | 7.49% | 8.82% | -20.05% | -42.48% | 1.19% |
Profit Margin | 5.93% | 6.10% | 7.02% | -22.11% | -37.02% | 2.89% |
Free Cash Flow Margin | 12.17% | 8.48% | 16.59% | 21.65% | 7.40% | -11.28% |
EBITDA | 157.58 | 133.41 | 152.46 | -187.97 | -324.45 | 47.9 |
EBITDA Margin | 11.35% | 10.92% | 11.87% | -16.62% | -37.98% | 4.32% |
D&A For EBITDA | 44.02 | 41.98 | 39.27 | 38.71 | 38.39 | 34.68 |
EBIT | 113.56 | 91.43 | 113.18 | -226.68 | -362.84 | 13.21 |
EBIT Margin | 8.18% | 7.49% | 8.82% | -20.05% | -42.48% | 1.19% |
Effective Tax Rate | 21.83% | - | 7.50% | - | - | - |
Revenue as Reported | 1,389 | 1,221 | 1,284 | 1,131 | 854.22 | 1,109 |
Advertising Expenses | - | 19.4 | 17.23 | 14.98 | 90.22 | 106.37 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.